Advanced searches left 3/3

Hemolytic Anemia - Springer Nature

Summarized by Plex Scholar
Last Updated: 04 August 2022

* If you want to update the article please login/register

Autoimmune hemolytic anemia in patients with relapsed Hodgkin’s lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1

Penpulimab, an anti-programmed cell death 1 monoclonal antibody, was approved in China in August 2021 for the treatment of adult patients with the relapsed or refractory classic Hodgkin's lymphoma with at least second-line chemotherapy. Penpulimab is now in clinical trials in China and Australia for the treatment of nasopharyngeal cancer and non-small cell lung cancer. Several research have shown that penpulimab is safe and effective, and no immune-related adverse events above grade 3 have been reported. After receiving penpulimab monotherapy, a 60-year-old woman with relapsed Hodgkinu2019s lymphoma developed nausea and exhaustion. From this experience, we know that acute AIHA can develop after penpulimab use similar to other PD-1 antibodies. In addition, we recommend regular direct antiglobulin testing, as well as haptoglobin, lactate dehydrogenase, and other hemolysis-related laboratory procedures in patients prescribed penpulimab and similar drugs for early diagnosis and therapy of AIHA.

Source link: https://doi.org/10.1007/s10637-022-01254-2


Heme-stress activated NRF2 skews fate trajectories of bone marrow cells from dendritic cells towards red pulp-like macrophages in hemolytic anemia

During hemolysis, specialized bone marrow-derived macrophages with a high heme-metabolism capacity orchestrate disease transformation by removing damaged erythrocytes and heme-protein complexes from the blood and encouraging iron recycling for erythropoiesis. To determine myeloid differentiation under heme strain, we used single-cell RNA sequencing of GM-CSF-supplemented mouse bone marrow cultures to determine myeloid differentiation under heme stress. We discovered that heme-triggered NRF2 signaling accelerated bone marrow cell differentiation toward antioxidant, iron-recycling macrophages, limiting the formation of dendritic cells in heme-exposed bone marrow cultures. Heme removed the ability of GM-CSF-supplemented bone marrow cultures to produce antigen-specific CD4 T cells from Heme's bone marrow cultures to stimulate antigen-specific CD4 T cells. The heme-induced macrophage growth was replicated in hemolytic mice with sickle cell disease and spherocytosis, which was also associated with reduced dendritic cell counts in the spleen, according to hemolytic mice with chronic dendritic cell depletion and concurrent dendritic cell depletion.

Source link: https://doi.org/10.1038/s41418-022-00932-1


Hereditary nonspherocytic hemolytic anemia caused by glucose-6-phosphate isomerase (GPI) deficiency in a Chinese patient: a case report

Glucose phosphate isomerase deficiency is a rare autosomal recessive disorder that results in hereditary nonspherocytic hemolytic anemia. The cause of GPI deficiency is a chromosome 19q13 mutation of the GPI gene, whether homozygous or compound heterozygous mutation on chromosome 19q13. Case study The 5-month-old boy was given repeated episodes of jaundice after birth. Mutation p. Gly271Glufs*131 is a novel frameshift null mutation in GPI deficiency. Conclusion In a patient with recurrent jaundice since birth, mutations in the GPI gene associated with HNSHA should be tested. The c. 812delG variant may be a unique deletion of the GPI gene.

Source link: https://doi.org/10.1186/s12887-022-03522-9


Clinical and surgical outcomes of splenectomy for autoimmune hemolytic anemia

Introduction After splenectomy in patients with primary and secondary autoimmune hemolytic anemia, we investigated short and long-term remission rates. Methods All adults who underwent splenectomy for primary or secondary AIHA at a single center were retrospectively assessed. In 22 of 36 patients, complete response was achieved, partial response in 3, no response in 11 — no response in 11. Compared to 100% with secondary AIHA, 80% of partial responders with primary AIHA required maintenance therapy compared to 100% with secondary AIHA. In the majority of patients with AIHA, stemmectomy is associated with short- and long-term improvement in anemia and hemolysis.

Source link: https://doi.org/10.1007/s00464-022-09116-x


Hemolytic anemia in COVID-19

COVID-19 is a global pandemic caused by the severe acute respiratory syndrome-coronavirus 2's acute respiratory syndrome-coronavirus 2. Hemolytic anemia has been attributed to COVID-19 induction of autoantibodies or directly through CD147 or erythrocyte-mediated erythrocyte injury. Thus, early detection and management of COVID-19 patients may prevent the poor prognostic results in COVID-19 patients. Moreover, since hemolytic exacerbations may result from medications for COVID-19 therapy and anti-SARS-CoV-2 vaccination, continued monitoring for complications is also required.

Source link: https://doi.org/10.1007/s00277-022-04907-7

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions